Magnetic assisted curcumin drug delivery using folate receptor targeted hybrid casein-calcium ferrite nanocarrier

Receptor targeted nanocarriers in the multimodal delivery of cancer therapeutics with minimal side effects are being intensively researched. In this study, folate receptor targeted hybrid protein inorganic nanocarrier was investigated for magnetic-assisted curcumin drug delivery. The protein carrier...

Full description

Saved in:
Bibliographic Details
Published inJournal of drug delivery science and technology Vol. 52; pp. 509 - 520
Main Authors K. Purushothaman, Bindhya, Harsha S, Muni, Maheswari, P. Uma, Sheriffa Begum, K.M. Meera
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.08.2019
Subjects
Curcumin
Drug delivery
Folic acid
Hybrid carrier
Kinetic modeling
Magnetic assisted
Magnetic assisted
Curcumin
Drug delivery
Kinetic modeling
Hybrid carrier
Folic acid
Online AccessGet full text

Cover

More Information
Summary:Receptor targeted nanocarriers in the multimodal delivery of cancer therapeutics with minimal side effects are being intensively researched. In this study, folate receptor targeted hybrid protein inorganic nanocarrier was investigated for magnetic-assisted curcumin drug delivery. The protein carrier, casein was hybridized with superparamagnetic calcium ferrite nanoparticles (CFNP) in which the anti-cancer drug, curcumin (Cur) was encapsulated. Finally, folic acid (FA) was conjugated to enable receptor-mediated endocytosis. The synthesized materials were characterized using XRD, FTIR, SEM, VSM and DLS analysis confirming their formulation. The drug loading parameters were optimized by Taguchi technique. Curcumin release from the carrier was studied under the influence of pH, initial drug concentrations and magnetic field. Drug release rate was higher in acidic conditions, increased drug concentrations and under the influence of magnetic field. The drug release mechanism from the carrier were proposed using different kinetic models. Biocompatibility and cytotoxicity tests were performed for the synthesized drug carrier systems using L929 murine fibroblast and MCF-7 breast cancer cells, respectively. The IC50 value reduced nearly six fold for MCF-7 cells, for casein-Cur with FA conjugation in comparison to the carrier without FA. The study clearly demonstrated casein-CFNP-Cur-FA as a novel potential formulation for targeted drug delivery. [Display omitted]
ISSN:1773-2247
DOI:10.1016/j.jddst.2019.05.010